Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Down to $14.64

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) shares gapped down before the market opened on Friday . The stock had previously closed at $14.64, but opened at $14.18. Day One Biopharmaceuticals shares last traded at $14.50, with a volume of 70,591 shares traded.

Analyst Ratings Changes

DAWN has been the topic of a number of recent research reports. Needham & Company LLC restated a “buy” rating and set a $34.00 price objective on shares of Day One Biopharmaceuticals in a research note on Tuesday, September 12th. The Goldman Sachs Group reduced their price objective on Day One Biopharmaceuticals from $63.00 to $54.00 and set a “buy” rating on the stock in a research note on Tuesday, August 8th. Wedbush restated an “outperform” rating and set a $38.00 price objective on shares of Day One Biopharmaceuticals in a research note on Tuesday, September 12th. Finally, HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Day One Biopharmaceuticals in a research note on Tuesday, August 8th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $42.14.

Day One Biopharmaceuticals Price Performance

The firm has a market capitalization of $1.21 billion, a PE ratio of -6.08 and a beta of -2.01. The stock has a 50-day moving average price of $13.18 and a 200-day moving average price of $13.70.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its earnings results on Monday, August 7th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.01). As a group, equities research analysts predict that Day One Biopharmaceuticals, Inc. will post -2.45 earnings per share for the current fiscal year.

Insider Activity at Day One Biopharmaceuticals

In related news, CEO Jeremy Bender sold 2,996 shares of the business’s stock in a transaction dated Thursday, August 17th. The stock was sold at an average price of $13.86, for a total value of $41,524.56. Following the completion of the sale, the chief executive officer now directly owns 704,224 shares of the company’s stock, valued at $9,760,544.64. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders sold a total of 4,586 shares of company stock valued at $63,562 over the last three months. 8.80% of the stock is owned by insiders.

Institutional Trading of Day One Biopharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Laurion Capital Management LP increased its holdings in Day One Biopharmaceuticals by 5.4% in the fourth quarter. Laurion Capital Management LP now owns 15,000 shares of the company’s stock valued at $323,000 after buying an additional 763 shares during the last quarter. Parkwood LLC boosted its stake in Day One Biopharmaceuticals by 4.8% in the fourth quarter. Parkwood LLC now owns 19,353 shares of the company’s stock valued at $416,000 after acquiring an additional 878 shares during the period. California State Teachers Retirement System boosted its stake in Day One Biopharmaceuticals by 9.5% in the third quarter. California State Teachers Retirement System now owns 10,929 shares of the company’s stock valued at $219,000 after acquiring an additional 944 shares during the period. Rhumbline Advisers boosted its stake in Day One Biopharmaceuticals by 2.4% in the first quarter. Rhumbline Advisers now owns 43,996 shares of the company’s stock valued at $588,000 after acquiring an additional 1,043 shares during the period. Finally, Alyeska Investment Group L.P. boosted its stake in Day One Biopharmaceuticals by 0.8% in the fourth quarter. Alyeska Investment Group L.P. now owns 143,218 shares of the company’s stock valued at $3,082,000 after acquiring an additional 1,075 shares during the period.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.